[Radioimmunoimaging assay of ovarian tumor with 99mTc labeled anti-carcinoembryonic antigen monoclonal antibody].
Radioimmunoimaging (RI I) assay with 99mTc labeled anti-CEA monoclonal antibody was performed in 31 patients with suspected primary or recurrent malignant ovarian tumor. The radiation dose raging from 920MBq to 110MBq(1mgIgG) was administered i.v. for each patient. Anterior-posterior views of the pelvis and abdomen were obtained routinely with gamma-camera during 18-24 hour after the application of antibody. The results of RII were compared with the findings in operation or CT examination. Sensitivity in diagnosis was 100% (13/13), specificity was 94%(16/17) and metastatic foci sensitivity was 63%(10/16). The serum CA125 in this study appeared to be correlated with the results of RII. However, in 2 patients with normal serum CA125 titers RII revealed true positive. The preliminary clinical results of RII with 99mTc-MAb showed that RII is a promising method for the detection of malignant ovarian tumors.
Wu
L Y
LY
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing.
Wu
A R
AR
Zhan
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D018283:Cystadenocarcinoma, Papillary / Q000000981:diagnostic imaging*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging*; D016719:Radioimmunodetection; D013667:Technetium
D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen; D002272:Carcinoembryonic Antigen; D013667:Technetium